Melanoma & Skin Cancer | Specialty

NCCN's 16th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 24th 2011

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

Roche Files Vemurafenib for Regulatory Approval

May 17th 2011

Vemurafenib works by selectively targeting and inhibiting a mutated form of the BRAF protein found in about half of all cases of melanoma

Ipilimumab's Unique Side Effects Require Unique Management

May 6th 2011

The FDA recently approved the immunotherapy ipilimumab (Yervoy) as a second-line treatment for patients with metastatic melanoma

Novel Therapies Prompt Push for New Paradigms to Evaluate Treatments

May 3rd 2011

As immunotherapy options grow, oncologists will need new frameworks of reference for evaluating whether patients are benefiting from the treatments

Ipilimumab's Unique Side Effects Require Unique Management

May 2nd 2011

Researchers at SFOA have examined the challenges ipilimumab's unique side-effect profile presents to oncology professionals

Cancer as Comedy? Medicine Meets Entertainment in 'The Big C'

April 16th 2011

The ambitious effort to portray the cancer journey of one fictional patient marks an intersection of medicine and entertainment that has attracted widespread attention

March Net Guide: Melanoma

April 7th 2011

A look at cancer centers, resources, clinical trials, CME and other offerings from across the web

Biomarker Test Shows Promise in Diagnoses

April 6th 2011

A biomarker test for DNA methylation identified 22 gene sites able to differentiate between melanoma and nonmelanoma lesions

Drugmaker Prepares to Ship New Melanoma Drug

March 29th 2011

Bristol-Myers Squibb plans to start rolling out its newly approved melanoma drug ipilimumab (Yervoy) in the next several weeks

Ipilimumab Approved as Melanoma Treatment

March 25th 2011

The FDA has approved the novel drug ipilimumab for the treatment of patients with metastatic melanoma

New Melanoma Drug Applauded

March 25th 2011

Cancer researchers and patient advocates are hailing the FDA's approval of Yervoy (ipilimumab)

Independence and Tenacity Anchor Immunology Pioneer

March 25th 2011

James P. Allison has never hesitated to buck the system

Dr. Pecora on his Personal Involvement in Research

March 15th 2011

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

Net Guides: Melanoma

March 13th 2011

Useful Online Resources and Clinical Trials for Melanoma

Crisis Averted? Manufacturers Scurry to Meet Demand for Drugs

March 12th 2011

The shortage, which began in 2009, accelerated in 2010, and has shown no signs of abatement so far in 2011, according to Erin R. Fox, PharmD, manager of the Drug Information Service at University of Utah Health Care

Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma

March 12th 2011

Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade

The Emperor of All Maladies: Documenting Cancer's Long Reign

March 12th 2011

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

Effects of UV Radiation Are Cumulative

March 9th 2011

An article in Oncogene further explains how ultraviolet (UV) radiation helps transform skin cells into basal cell carcinoma.

Dr. Pearlstone on Technological Challenges

March 8th 2011

John Theurer Cancer Center Opens New Comprehensive Facility

March 4th 2011

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States